CASI Pharmaceuticals Overview

  • Year Founded
  • 1991

Year Founded

  • Status
  • Public

  • Employees
  • 214

Employees

  • Stock Symbol
  • CASIF

Stock Symbol

  • Investments
  • 11

  • Share Price
  • $0.10
  • (As of Friday Closing)

CASI Pharmaceuticals General Information

Description

CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.

Contact Information

Formerly Known As
EntreMed, Casi Pharmaceuticals Holdings
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Room 1701-1703, Tower 1, Huamao Office Building
  • Number 81, Jianguo Road, Chaoyang District
  • Beijing, 100025
  • China
+86 010
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • Room 1701-1703, Tower 1, Huamao Office Building
  • Number 81, Jianguo Road, Chaoyang District
  • Beijing, 100025
  • China
+86 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CASI Pharmaceuticals Stock Performance

As of 13-Nov-2026, CASI Pharmaceuticals’s stock price is $0.10. Its current market cap is $2.1M with 20.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.10 $0.10 $0.05 - $1.35 $2.1M 20.6M 2.4K -$2.00

CASI Pharmaceuticals Financials Summary

As of 30-Jun-2026, CASI Pharmaceuticals has a trailing 12-month revenue of $20.1M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 25,348 31,636 42,153 81,425
Revenue 20,114 20,712 28,537 33,879
EBITDA (43,938) (35,376) (23,119)
Net Income (43,959) (48,058) (39,258) (26,938)
Total Assets 21,063 25,650 53,674 75,268
Total Debt 40,497 27,486 22,141 21,239
Public Fundamental Data provided by Morningstar, Inc. disclaimer

CASI Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CASI Pharmaceuticals‘s full profile, request access.

Request a free trial

CASI Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antib
Drug Discovery
Beijing, China
214 As of 2025

Utrecht, Netherlands
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CASI Pharmaceuticals Competitors (52)

One of CASI Pharmaceuticals’s 52 competitors is Lava Therapeutics, a Formerly VC-backed company based in Utrecht, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lava Therapeutics Formerly VC-backed Utrecht, Netherlands
AVEO Oncology Formerly VC-backed Boston, MA
Alaunos Therapeutics Formerly VC-backed Fort Lauderdale, FL
Ayala Pharmaceuticals Corporation Wilmington, DE
Immunocore Holdings Formerly VC-backed Abingdon, United Kingdom
You’re viewing 5 of 52 competitors. Get the full list »

CASI Pharmaceuticals Patents

CASI Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022388575-A1 Vcp/p97 inhibitor for the treatment of cancer Inactive 10-Nov-2021
EP-4429772-A1 Vcp/p97 inhibitor for the treatment of cancer Pending 10-Nov-2021
EP-4429772-A4 Vcp/p97 inhibitor for the treatment of cancer Pending 10-Nov-2021
US-20250049800-A1 Vcp/p97 inhibitor for the treatment of cancer Pending 10-Nov-2021
AU-2021338773-A1 Methods of blood screening Pending 10-Sep-2020 G01N33/80
To view CASI Pharmaceuticals’s complete patent history, request access »

CASI Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CASI Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CASI Pharmaceuticals‘s full profile, request access.

Request a free trial

CASI Pharmaceuticals Investments & Acquisitions (11)

CASI Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with CASI Pharmaceuticals (CB-5339). The deal was made on 21-Jul-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CASI Pharmaceuticals (CB-5339) 21-Jul-2023 Corporate Asset Purchase Drug Delivery
Precision Autoimmune Therapeutics 05-Jul-2022 Early Stage VC Drug Discovery
Juventas (Drug Discovery) 30-Sep-2020 Early Stage VC Drug Discovery
Juventas Cell Therapy (Worldwide Rights of Anti-CD19 T-Cell Therapy in Tianjin City, China) 03-Dec-2019 Corporate Asset Purchase Buildings and Property
Juventas (Drug Discovery) 01-Jun-2019 Early Stage VC Drug Discovery
You’re viewing 5 of 11 investments and acquisitions. Get the full list »

CASI Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view CASI Pharmaceuticals’s complete esg history, request access »

CASI Pharmaceuticals Exits (1)

CASI Pharmaceuticals’s most recent exit was on 07-Apr-2004 from MaxCyte. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
MaxCyte 07-Apr-2004 Completed
  • 4 buyers
To view CASI Pharmaceuticals’s complete exits history, request access »

CASI Pharmaceuticals FAQs

  • When was CASI Pharmaceuticals founded?

    CASI Pharmaceuticals was founded in 1991.

  • Where is CASI Pharmaceuticals headquartered?

    CASI Pharmaceuticals is headquartered in Beijing, China.

  • What is the size of CASI Pharmaceuticals?

    CASI Pharmaceuticals has 214 total employees.

  • What industry is CASI Pharmaceuticals in?

    CASI Pharmaceuticals’s primary industry is Drug Discovery.

  • Is CASI Pharmaceuticals a private or public company?

    CASI Pharmaceuticals is a Public company.

  • What is CASI Pharmaceuticals’s stock symbol?

    The ticker symbol for CASI Pharmaceuticals is CASIF.

  • What is the current stock price of CASI Pharmaceuticals?

    As of 13-Nov-2026 the stock price of CASI Pharmaceuticals is $0.10.

  • What is the current market cap of CASI Pharmaceuticals?

    The current market capitalization of CASI Pharmaceuticals is $2.1M.

  • What is CASI Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for CASI Pharmaceuticals is $20.1M.

  • Who are CASI Pharmaceuticals’s competitors?

    Lava Therapeutics, AVEO Oncology, Alaunos Therapeutics, Ayala Pharmaceuticals, and Immunocore Holdings are some of the 52 competitors of CASI Pharmaceuticals.

  • What is CASI Pharmaceuticals’s annual earnings per share (EPS)?

    CASI Pharmaceuticals’s EPS for 12 months was -$2.00.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process